ek0991  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Boster Bio ek0991
    Ek0991, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ek0991/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ek0991 - by Bioz Stars, 2022-07
    93/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • igfbp7  (Boster Bio)
    93
    Boster Bio igfbp7
    <t>IGFBP7</t> serum level in STS patients. A. Mann-Whitney test shows that serum levels of STS patients were significantly higher than the control, revealing a threshold level of 25 ng/ml. B. Kruskal-Wallis analysis followed by Dunnett test demonstrated that synovial sarcoma (SS) and liposarcoma (LS) had significantly higher IGFBP7 levels when compared to both the control and the other tumors (**P
    Igfbp7, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igfbp7/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    igfbp7 - by Bioz Stars, 2022-07
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    IGFBP7 serum level in STS patients. A. Mann-Whitney test shows that serum levels of STS patients were significantly higher than the control, revealing a threshold level of 25 ng/ml. B. Kruskal-Wallis analysis followed by Dunnett test demonstrated that synovial sarcoma (SS) and liposarcoma (LS) had significantly higher IGFBP7 levels when compared to both the control and the other tumors (**P

    Journal: American Journal of Cancer Research

    Article Title: Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma

    doi:

    Figure Lengend Snippet: IGFBP7 serum level in STS patients. A. Mann-Whitney test shows that serum levels of STS patients were significantly higher than the control, revealing a threshold level of 25 ng/ml. B. Kruskal-Wallis analysis followed by Dunnett test demonstrated that synovial sarcoma (SS) and liposarcoma (LS) had significantly higher IGFBP7 levels when compared to both the control and the other tumors (**P

    Article Snippet: Individual serum samples (50 µl) were mixed with 450 µl dilution buffer and the concentration of IGFBP7 (ELISA kit from Boster Biological Technology Co., Fremont, CA, USA) was determined according to manufacturer’s instructions.

    Techniques: MANN-WHITNEY

    IGFBP7 protein expression. A. Representative immunostaining of IGFBP7 in leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS). A stronger expression is evident in metastatic patients, with predominant cytoplasmatic distribution (IHC 20 ×). B. Mann-Whitney analysis reveals statistically significant higher IGFBP7 staining levels in metastatic compared to non metastatic samples. C. Kaplan-Meier survival curves show the higher probability of the metastatic event in patients with high IGFBP7 expression (score 5-6).

    Journal: American Journal of Cancer Research

    Article Title: Tissue and serum IGFBP7 protein as biomarker in high-grade soft tissue sarcoma

    doi:

    Figure Lengend Snippet: IGFBP7 protein expression. A. Representative immunostaining of IGFBP7 in leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma (UPS). A stronger expression is evident in metastatic patients, with predominant cytoplasmatic distribution (IHC 20 ×). B. Mann-Whitney analysis reveals statistically significant higher IGFBP7 staining levels in metastatic compared to non metastatic samples. C. Kaplan-Meier survival curves show the higher probability of the metastatic event in patients with high IGFBP7 expression (score 5-6).

    Article Snippet: Individual serum samples (50 µl) were mixed with 450 µl dilution buffer and the concentration of IGFBP7 (ELISA kit from Boster Biological Technology Co., Fremont, CA, USA) was determined according to manufacturer’s instructions.

    Techniques: Expressing, Immunostaining, Immunohistochemistry, MANN-WHITNEY, Staining